Transport and toxicity of 5-fluorouracil, doxorubicin, and cyclophosphamide in in vitro placental barrier model based on BeWo b30 cells


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

An in vitro placental barrier model based on human choriocarcinoma BeWo b30 cell line was considered as a method of preclinical study of the transport and toxicity of antitumor agents and other organic compounds. Low permeabilities were found for 5-fluorouracil as an example of hydrophilic compound and for doxorubicin as an example of a lipophilic compound with a high degree of binding to proteins and DNA and a high permeability was found for cyclophosphamide as an example of lipophilic compound with a low degree of binding to proteins. Using impedance spectrometry and cell viability assessment via reduction of resazurin to resorufin, a pronounced cytotoxic effect of doxorubicin and good tolerance of 5-fluorouracil and cyclophosphamide by the cells were shown for drug concentrations equal to the maximum concentrations in the patients’ blood during the treatment of breast cancer.

Авторлар туралы

E. Knyazev

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Scientific Research Center Bioclinicum; Far Eastern Federal University

Хат алмасуға жауапты Автор.
Email: e.knyazev@bioclinicum.com
Ресей, 16/10 ul. Miklukho-Maklaya, Moscow, 117997; Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091

S. Nikulin

Scientific Research Center Bioclinicum; Far Eastern Federal University

Email: e.knyazev@bioclinicum.com
Ресей, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091

A. Khristichenko

Scientific Research Center Bioclinicum; D. Rogachev Federal Scientific and Clinical Center for Pediatric Hematology, Oncology, and Immunology

Email: e.knyazev@bioclinicum.com
Ресей, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 1 ul. Samory Machela, Moscow, 117997

T. Gerasimenko

Scientific Research Center Bioclinicum

Email: e.knyazev@bioclinicum.com
Ресей, Build. 85, 2ul. Ugreshskaya, Moscow, 115088

O. Kindeeva

Scientific Research Center Bioclinicum; Far Eastern Federal University

Email: e.knyazev@bioclinicum.com
Ресей, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091

V. Petrov

Scientific Research Center Bioclinicum; Institute of Nanotechnology of Microelectronics, Russian Academy of Sciences

Email: e.knyazev@bioclinicum.com
Ресей, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 32A Leninsky prosp., Moscow, 119991

G. Belyakova

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Email: e.knyazev@bioclinicum.com
Ресей, Build. 2, 8 Trubetskaya ul., Moscow, 119991

D. Maltseva

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Scientific Research Center Bioclinicum

Email: e.knyazev@bioclinicum.com
Ресей, 16/10 ul. Miklukho-Maklaya, Moscow, 117997; Build. 85, 2ul. Ugreshskaya, Moscow, 115088


© Springer Science+Business Media, LLC, part of Springer Nature, 2019

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>